- Home
- SBGI vs GERN Comparison
SBGI vs GERN Comparison
Compare SBGI & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBGI
- GERN
- Stock Information
- Founded
- SBGI 1986
- GERN 1990
- Country
- SBGI United States
- GERN United States
- Employees
- SBGI N/A
- GERN N/A
- Industry
- SBGI Broadcasting
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- SBGI Industrials
- GERN Health Care
- Exchange
- SBGI Nasdaq
- GERN Nasdaq
- Market Cap
- SBGI 886.6M
- GERN 740.5M
- IPO Year
- SBGI 1995
- GERN 1996
- Fundamental
- Price
- SBGI $15.92
- GERN $1.14
- Analyst Decision
- SBGI Buy
- GERN Buy
- Analyst Count
- SBGI 5
- GERN 7
- Target Price
- SBGI $21.00
- GERN $3.00
- AVG Volume (30 Days)
- SBGI 595.5K
- GERN 8.7M
- Earning Date
- SBGI 11-05-2025
- GERN 11-05-2025
- Dividend Yield
- SBGI 6.34%
- GERN N/A
- EPS Growth
- SBGI N/A
- GERN N/A
- EPS
- SBGI N/A
- GERN N/A
- Revenue
- SBGI $3,337,000,000.00
- GERN $183,403,000.00
- Revenue This Year
- SBGI N/A
- GERN $166.20
- Revenue Next Year
- SBGI $9.50
- GERN $55.83
- P/E Ratio
- SBGI N/A
- GERN N/A
- Revenue Growth
- SBGI N/A
- GERN 522.13
- 52 Week Low
- SBGI $11.89
- GERN $1.04
- 52 Week High
- SBGI $18.46
- GERN $4.21
- Technical
- Relative Strength Index (RSI)
- SBGI 55.53
- GERN 47.42
- Support Level
- SBGI $14.52
- GERN $1.05
- Resistance Level
- SBGI $17.88
- GERN $1.28
- Average True Range (ATR)
- SBGI 0.88
- GERN 0.07
- MACD
- SBGI -0.07
- GERN 0.01
- Stochastic Oscillator
- SBGI 40.96
- GERN 47.92
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.